Drug access program offers hope for rare blood disorder patients
NCT ID NCT05221619
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This program provides continued treatment with nipocalimab for people with warm autoimmune hemolytic anemia (wAIHA) who have already shown improvement in a previous study. Participants receive the drug by IV infusion every 2 or 4 weeks. The goal is to keep their hemoglobin levels stable and maintain clinical benefit.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- nipocalimab
- What this could lead to
- If successful, this program could help maintain stable hemoglobin levels in people with warm autoimmune hemolytic anemia, offering continued disease control.
- What could go wrong
- This is a small, open-label access program, not a controlled trial. Results may not apply to all patients, and long-term risks remain unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WARM AUTOIMMUNE HEMOLYTIC ANEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug calm the immune System's attack on blood cells?
- New pill could help patients with rare blood disorder
- New drug IASO-782 aims to tame immune attacks on blood cells
- Experimental immune therapy for stubborn anemia shows early promise but trial stalls
- Gene-Edited immune cells take on autoimmune blood diseases
- New combo aims to tame autoimmune anemia without Long-Term steroids